Clinical investigation of new medicinal products for the treatment of acute coronary syndrome

  • Email
  • Help
Current effective version

Adopted guideline

First version enters into effect 01/03/2018  - see below

Reference numberEMA/CHMP/760125/2016
Published20/09/2017
Effective from01/03/2018
KeywordsAcute coronary syndrome, STE-ACS, NSTE-ACS
DescriptionThis guideline replaces 'Points to consider on the clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) without persistent ST segment elevation' (CPMP/EWP/570/98) and 'Points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction (STEMI)' (CPMP/EWP/967/01).


Document history

First version

 

Adopted guideline
 

 

Overview of comments


Draft guideline
 

Concept paper

Published: 20/09/2017
Effective from: 01/03/2018

 

Published: 26/09/2017
 

Published: 27/04/2016
 

Published: 15/10/2014

Superseeded document
(from 01/03/2018)

Current version

Adopted guidelineIn operation: 01/09/2000 - 01/03/2018


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more